BioMarin Pharmaceutical Inc. (BMRN)

83.99
NASDAQ
Prev Close 82.95
Day Low/High 82.66 / 84.02
52 Wk Low/High 79.13 / 106.74
Exchange NASDAQ
Shares Outstanding 179.07B
Market Cap 14.85B
Div & Yield N.A. (N.A)
Sanofi Presses Medivation to Hold Talks After $9.3B Offer

Sanofi Presses Medivation to Hold Talks After $9.3B Offer

The French pharmaceuticals company takes its campaign to snare the oncology specialist public.

Biotech Stock Mailbag: Is There a Future for Sarepta Therapeutics?

Biotech Stock Mailbag: Is There a Future for Sarepta Therapeutics?

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

BioMarin Enrolls First Patient In Phase 1/2 Trial Of NAGLU Fusion Protein BMN 250 For Treatment Of MPS IIIB (Sanfilippo B Syndrome)

BioMarin Enrolls First Patient In Phase 1/2 Trial Of NAGLU Fusion Protein BMN 250 For Treatment Of MPS IIIB (Sanfilippo B Syndrome)

European Commission Grants BMN 250 Orphan Drug Designation to Treat Ultra-Rare Condition

Jim Cramer's Top Takeaways: Intel, BioMarin Pharmaceuticals

Jim Cramer's Top Takeaways: Intel, BioMarin Pharmaceuticals

Cramer says splitting itself in two would revitalize Intel and make it attractive to investors.

Jim Cramer's 'Mad Money' Recap: This Market Is Rising No Matter What You Think

Jim Cramer's 'Mad Money' Recap: This Market Is Rising No Matter What You Think

Some people can't accept that things are improving, but that means the market will continue to go higher, Cramer says.

BioMarin To Highlight Breadth Of Innovative Development Pipeline At R&D Day On April 20th In New York

BioMarin To Highlight Breadth Of Innovative Development Pipeline At R&D Day On April 20th In New York

Key development updates will include preliminary data with BMN 270, gene therapy for hemophilia A, and one year data with vosoritide for achondroplasia

Anavex Plays the Orphan Drug Stock Promotion Game

Anavex Plays the Orphan Drug Stock Promotion Game

Too many investors have a fundamental misunderstanding about the significance of orphan drug designation. I should say, insignificance, because the FDA delineation, on its own, means very little.

BioMarin (BMRN) Stock is the 'Chart of the Day'

BioMarin (BMRN) Stock is the 'Chart of the Day'

BioMarin (BMRN) stock is Thursday's 'Chart of the Day.'

BioMarin Has Juice Left in the Tank

BioMarin Has Juice Left in the Tank

The big downtrend line was broken decisively.

Chart of the Day: BioMarin Pharmaceutical

The big downtrend line was broken decisively.

Sell These 5 Toxic Stocks Now, Before It's Too Late

Sell These 5 Toxic Stocks Now, Before It's Too Late

These five stocks could be toxic to your portfolio in April.

Biomarin Pharmaceutical (BMRN) Strong On High Relative Volume Today

Biomarin Pharmaceutical (BMRN) Strong On High Relative Volume Today

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a strong on high relative volume candidate

3 Stocks Pushing The Drugs Industry Downward

3 Stocks Pushing The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

A Rolling-Nowhere Market Gathers More Bears

A less-bullish view is starting to spread.

Biomarin Pharmaceutical (BMRN) Strong On High Relative Volume Today

Biomarin Pharmaceutical (BMRN) Strong On High Relative Volume Today

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a strong on high relative volume candidate

BioMarin PKU Drug Shows Mixed Results in Pivotal Study

BioMarin PKU Drug Shows Mixed Results in Pivotal Study

Based on these study results, BioMarin intends to file pegvaliase for approval with the FDA by the end of the year, 'subject to further discussions' with the agency.

Insider Trading Alert - BRT, BMRN And CSGS Traded By Insiders

Insider Trading Alert - BRT, BMRN And CSGS Traded By Insiders

Stocks with insider trader activity include BRT, BMRN and CSGS

Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem

Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem

TheStreet's Senior Columnist Adam Feuerstein answers reader questions about biotech stocks.

BMRN, INCY And ALXN, Pushing Drugs Industry Downward

BMRN, INCY And ALXN, Pushing Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Jim Cramer Says BioMarin Is the Last Bear Market

Jim Cramer Says BioMarin Is the Last Bear Market

TheStreet’s Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on shares of BioMarin Pharmaceutical.

Jim Cramer: Bear Markets in Many Sectors Have Ended

Jim Cramer: Bear Markets in Many Sectors Have Ended

Cramer is watching the FANG stocks as well as BioMarin Pharmaceutical.

JPMorgan's 7 Best Stock Picks With Near-Term Catalysts

JPMorgan's 7 Best Stock Picks With Near-Term Catalysts

Looking for quick profit? Consider companies that have upcoming events that could boost their stock prices. Here are seven stocks chosen by JPMorgan with upcoming catalysts.

Biomarin Drug Provides 'Substantial Benefit' to Kids with Rare, Fatal Brain Disease

Biomarin Drug Provides 'Substantial Benefit' to Kids with Rare, Fatal Brain Disease

If approved, the Biomarin drug will become the first effective treatment for CLN2 disease, a form of Batten disease.

TheStreet Quant Rating: D+ (Sell)